2.1
Cladribine (Mavenclad, Merck Serono) is indicated for 'the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features'.
2 Information about cladribine
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for cladribine.
Price
2.3
The list price is £2,047.24 per 10 mg tablet (excluding VAT, BNF online, November 2024). Costs may vary in different settings because of negotiated procurement discounts.